Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)

NCT03583710 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03583710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03583710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 3
Overall status
Recruiting
Start date
August 20, 2018
Completion date
January 1, 2029
Enrollment
240 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

ensat stage i adrenal cortex carcinoma, ensat stage ii adrenal cortex carcinoma, ensat stage iii adrenal cortex carcinoma